Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Lipidor

Less than 1K followers
All
Press releases
ShowingAll content types

Regulatory press release25.05.2025 klo 18.25

Lipidor applies for bankruptcy

Lipidor
Regulatory press release24.05.2025 klo 13.40

Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis

Lipidor
Press release19.05.2025 klo 09.30

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2

Lipidor

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release09.05.2025 klo 15.25

Lipidor AB (publ) publishes annual report for 2024

Lipidor
Press release17.03.2025 klo 09.30

Lipidor announces all patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release28.02.2025 klo 09.30

Lipidor AB (publ) publishes year-end report for 2024

Lipidor
Press release21.01.2025 klo 09.00

Lipidor announces half of patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release03.12.2024 klo 09.00

Lipidor presents Nomination Committee

Lipidor
Press release20.11.2024 klo 09.00

Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"

Lipidor
Press release24.09.2024 klo 19.30

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

Lipidor
Regulatory press release28.08.2024 klo 09.30

Lipidor AB (publ) publishes interim report for Q2 2024

Lipidor
Press release20.08.2024 klo 14.50

Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan

Lipidor
Regulatory press release01.07.2024 klo 09.15

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue

Lipidor
Regulatory press release25.06.2024 klo 22.57

Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants

Lipidor
Regulatory press release13.06.2024 klo 21.46

Lipidor announces final outcome in the rights issue

Lipidor
Regulatory press release12.06.2024 klo 21.58

Lipidor announces preliminary outcome in the rights issue

Lipidor
Regulatory press release07.06.2024 klo 09.30

Last day of trading in unit rights in Lipidor's rights issue

Lipidor
Regulatory press release05.06.2024 klo 11.00

Bulletin from the Annual General Meeting of Lipidor AB (publ)

Lipidor
Regulatory press release29.05.2024 klo 09.30

Lipidor invites to digital presentations with Q&A

Lipidor
Regulatory press release29.05.2024 klo 09.00

Today the subscription period in Lipidor's rights issue begins

Lipidor